Pulsenmore Ltd. (PLSM)
| Market Cap | 20.36M -73.0% |
| Revenue (ttm) | 14.13M +352.3% |
| Net Income | -9.32M |
| EPS | -1.44 |
| Shares Out | 6.50M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,581 |
| Open | 2.330 |
| Previous Close | 2.220 |
| Day's Range | 2.280 - 2.360 |
| 52-Week Range | 2.220 - 12.970 |
| Beta | 0.40 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 31, 2026 |
About PLSM
Pulsenmore Ltd., a medical device company, engages in the research, development, manufacture, marketing, and sale of portable ultrasound solutions. The company provides Pulsenmore ES and Pulsenmore FC products. The company was incorporated in 2014 and is based in Omer, Israel.
Financial Performance
In 2025, Pulsenmore's revenue was 40.02 million, an increase of 314.28% compared to the previous year's 9.66 million. Losses were -15.85 million, -56.85% less than in 2024.
Financial numbers in ILS Financial StatementsNews
Pulsenmore expands its fertility platform into the UK
Pulsenmore (PLSM)has completed the registration of Pulsenmore FC with the MHRA, the UK regulatory authority responsible for medical devices. The registration enables the company to market the system i...
Pulsenmore Expands Its Fertility Platform into the UK
MHRA registration allows Pulsenmore FC to be marketed across the United Kingdom and Northern Ireland, extending the Company's home ultrasound platform into the UK fertility market where more than 100,...
Pulsenmore Expands into Fertility Care: Completes CE European Registration of Home Ultrasound System for Follicular Monitoring
The Pulsenmore FC system is designed to enable women undergoing IVF and fertility preservation treatments to self-perform ultrasound scans from home This registration marks the Company's second produ...
Pulsenmore reports 1H EPS ($1.83)
Reports 1H revenue $2.042M. “The first half of 2026 marked a transformative period for Pulsenmore (PLSM)as we initiated commercial operations in the United States following FDA authorization and achie...
Pulsenmore Ltd. Announces Financial Results and Business Highlights for the First Half of 2026
Management to Host Webcast today at 8:30 am ET to discuss Results and Provide Business Update OMER, Israel, Aug. 31, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a leading innovat...
Pulsenmore Ltd. To Announce Financial Results and Business Highlights and Hold Conference Call for the First Half of 2026
OMER, Israel, Aug. 24, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a leading innovator in remote maternal-fetal healthcare and home ultrasound solutions, today announces that it ...
Pulsenmore Expands Its Home Ultrasound Activity in Israel: Ichilov Adopts the Technology, Expanding Access to At-Home Pregnancy Monitoring
The Company's home ultrasound technology will be integrated at Lis Maternity and Women's Hospital at Ichilov, expanding the ability to incorporate at-home ultrasound scans as part of pregnancy monitor...
Pulsenmore Receives Second AI Grant Within One Month: Israel Innovation Authority Approves $1.27 Million for SmartScan AI Program
The new grant brings the total AI grants approved for Pulsenmore over the past month to approximately $1.6 million, supporting two programs with a combined scope of approximately $3.12 million. The pr...
Pulsenmore to participate in Israel’s Healthcare AI Regulatory Sandbox Program
Pulsenmore (PLSM)announced that it has been selected to participate in Israel’s Healthcare AI Regulatory Sandbox Program, established by the Israel Innovation Authority and the Ministry of Health. Pul...
Pulsenmore Selected for Israel Innovation Authority and Ministry of Health Program to Lead an $1 Million AI Development Project
The program is designed to enable Pulsenmore to develop and clinically validate AI applications that improve clinical workflow efficiency and enhance the scalability of the company's home ultrasound p...
Pulsenmore registers to sell 3.125M ordinary shares for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 3.125M ordinary shares. The company is not selling any shares under…
Pulsenmore announces $7.5M private placement
Pulsenmore (PLSM)announced that it has entered into a securities purchase agreement with a healthcare-focused institutional investor, for the purchase and sale of 1,562,500 ordinary shares and ordinar...
Pulsenmore Announces Pricing of $7.5 Million Private Placement with a Single Healthcare Focused Institutional Investor
RAMAT GAN, Israel, June 25, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a pioneer in home ultrasound technology, today announced that it has entered into a securities purchase ag...
Why Is Penny Stock Pulsenmore (PLSM) Up Today?
Pulsenmore stock rallied on Wednesday alongside a new strategic collaboration.
Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States
FDA-authorized home ultrasound technology to be integrated into Ouma Health's virtual maternity care model, creating a scalable pathway to expand the adoption of home ultrasound in prenatal care acros...
Pulsenmore Announces Full Year 2025 Financial Results and Webcast
Management to Host Conference Call and Webcast today at 8:30am ET to Discuss Results and Provide Business Update OMER, Israel, March 30, 2026 /PRNewswire/ – Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM...
Pulsenmore Announces Full Year 2025 Earnings Conference Call
OMER, Israel, March 25, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a pioneer in home ultrasound technology, today announced that it will release its financial results for full y...
Pulsenmore Ltd. Ordinary Shares trading resumes
09:39 EST Pulsenmore (PLSM)Ltd. Ordinary Shares trading resumes
Pulsenmore Ltd. Ordinary Shares trading halted, volatility trading pause
09:34 EST Pulsenmore (PLSM)Ltd. Ordinary Shares trading halted, volatility trading pause
Pulsenmore announces commercial engagement with TLC Perinatal PA
Pulsenmore (PLSM)announced a new commercial engagement with TLC Perinatal PA, a maternal-fetal medicine and women’s ultrasound practice in Maryland, as part of its growing U.S. rollout. In early Febru...
Pulsenmore Builds U.S. Momentum with Another Commercial Engagement Following FDA Clearance
OMER, Israel, Feb. 9, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a pioneer in home ultrasound technology, today announced a new commercial engagement with TLC Perinatal PA, a ma...
Pulsenmore announces first commercial engagement with medical center in the U.S.
Pulsenmore (PLSM)announced a first commercial engagement with a medical center in the U.S., following receipt of FDA approval for its home pregnancy ultrasound product. At the end of January 2026,
Pulsenmore Announces First Commercial Engagement with a Leading U.S.-Based Medical Center
OMER, Israel, Feb. 2, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a pioneer in home ultrasound technology, today announced a first commercial engagement with a medical center in ...
Pulsenmore and Clalit Health Services Launch First At-Home Follicular Monitoring Service for IVF and Fertility Preservation
Commercial agreement potentially valued at approximately $4.5 million over five years following 18 month pilot; Service to be deployed via Beilinson NEXT, Beilinson's virtual hospital RAMAT GAN, Israe...
Pulsenmore to commence trading on Nasdaq
Pulsenmore (PLSM)announced that its shares will begin trading on Nasdaq at the U.S. market open on January 21. The company’s shares will trade under the ticker symbol “PLSM” on the